300871 Stock Overview
Engages in the research and development, and manufacture of macrolides APIs and preparations in China and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 2/6 |
My Notes
Capture your thoughts, links and company narrative
Hvsen Biotechnology Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥10.37 |
| 52 Week High | CN¥16.49 |
| 52 Week Low | CN¥7.60 |
| Beta | 0.42 |
| 1 Month Change | 3.08% |
| 3 Month Change | -5.47% |
| 1 Year Change | 2.37% |
| 3 Year Change | -58.10% |
| 5 Year Change | n/a |
| Change since IPO | -74.85% |
Recent News & Updates
Hvsen Biotechnology Co., Ltd. (SZSE:300871) Not Doing Enough For Some Investors As Its Shares Slump 25%
Jan 03
Hvsen Biotechnology Co., Ltd. (SZSE:300871) Stock Catapults 26% Though Its Price And Business Still Lag The Industry
Nov 14Hvsen Biotechnology Co., Ltd.'s (SZSE:300871) Share Price Boosted 25% But Its Business Prospects Need A Lift Too
Sep 30Recent updates
Hvsen Biotechnology Co., Ltd. (SZSE:300871) Not Doing Enough For Some Investors As Its Shares Slump 25%
Jan 03Hvsen Biotechnology Co., Ltd. (SZSE:300871) Stock Catapults 26% Though Its Price And Business Still Lag The Industry
Nov 14Hvsen Biotechnology Co., Ltd.'s (SZSE:300871) Share Price Boosted 25% But Its Business Prospects Need A Lift Too
Sep 30Hvsen Biotechnology Co., Ltd. (SZSE:300871) Shares Could Be 21% Below Their Intrinsic Value Estimate
Aug 21Take Care Before Jumping Onto Hvsen Biotechnology Co., Ltd. (SZSE:300871) Even Though It's 27% Cheaper
Jun 05Hvsen Biotechnology Co., Ltd. (SZSE:300871) Stocks Shoot Up 37% But Its P/E Still Looks Reasonable
Mar 29Shareholder Returns
| 300871 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | 2.2% | 0.2% | -0.9% |
| 1Y | 2.4% | 12.8% | 22.0% |
Return vs Industry: 300871 underperformed the CN Pharmaceuticals industry which returned 8.3% over the past year.
Return vs Market: 300871 underperformed the CN Market which returned 18.4% over the past year.
Price Volatility
| 300871 volatility | |
|---|---|
| 300871 Average Weekly Movement | 6.1% |
| Pharmaceuticals Industry Average Movement | 5.4% |
| Market Average Movement | 6.8% |
| 10% most volatile stocks in CN Market | 10.7% |
| 10% least volatile stocks in CN Market | 4.0% |
Stable Share Price: 300871 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 300871's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 1,068 | n/a | www.whhsyy.com |
Hvsen Biotechnology Co., Ltd. engages in the research and development, and manufacture of macrolides APIs and preparations in China and internationally. Its products include tylvalosin tartrate powders and raw materials; florfenicol, cefquinome sulfate, and tildipirosin injections; and florfenicol powder/WSP, tylosin tartrate soluble powder, and tywasin premix products. The company produces various veterinary drug products of raw materials and preparations, as well as traditional Chinese medicines extractives.
Hvsen Biotechnology Co., Ltd. Fundamentals Summary
| 300871 fundamental statistics | |
|---|---|
| Market cap | CN¥1.71b |
| Earnings (TTM) | -CN¥45.75m |
| Revenue (TTM) | CN¥1.12b |
1.5x
P/S Ratio-37.4x
P/E RatioIs 300871 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 300871 income statement (TTM) | |
|---|---|
| Revenue | CN¥1.12b |
| Cost of Revenue | CN¥927.40m |
| Gross Profit | CN¥193.53m |
| Other Expenses | CN¥239.28m |
| Earnings | -CN¥45.75m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Apr 29, 2025
| Earnings per share (EPS) | -0.28 |
| Gross Margin | 17.27% |
| Net Profit Margin | -4.08% |
| Debt/Equity Ratio | 63.0% |
How did 300871 perform over the long term?
See historical performance and comparisonDividends
2.6%
Current Dividend Yield-98%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/31 12:07 |
| End of Day Share Price | 2025/01/27 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Hvsen Biotechnology Co., Ltd. is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jiarui Lu | Guosen Securities Co., Ltd. |
| Li Wu | Tianfeng Securities Brokerage Co., Ltd |